Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 0.01 | uM | 7 | 1250.00 | 859.67 | 1642.00 | 1850.00 | 0.8876 | 0.7955 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 7 | 1250.00 | 859.67 | 1004.00 | 1850.00 | 0.5427 | 0.1507 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 7 | 1250.00 | 859.67 | 1255.00 | 1850.00 | 0.6784 | 0.4080 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 7 | 1250.00 | 859.67 | 1912.00 | 1850.00 | 1.0335 | 1.0605 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 7 | 1250.00 | 859.67 | 1977.00 | 1850.00 | 1.0686 | 1.1238 |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 1807.00 | 1850.00 | 0.9768 | 0.9579 | |
| SK-BR-3 | Erlotinib | 0.1 | uM | 7 | 1250.00 | 859.67 | 1842.00 | 1850.00 | 0.9957 | 0.9922 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 7 | 1250.00 | 859.67 | 1844.00 | 1850.00 | 0.9968 | 0.9941 |
| SK-BR-3 | Linsitinib | 0.1 | uM | 7 | 1250.00 | 859.67 | 1884.00 | 1850.00 | 1.0184 | 1.0332 |
| SK-BR-3 | Erlotinib | 1 | uM | 7 | 1250.00 | 859.67 | 1633.00 | 1850.00 | 0.8827 | 0.7866 |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 7 | 1250.00 | 859.67 | 1276.00 | 1850.00 | 0.6897 | 0.4293 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 7 | 1250.00 | 859.67 | 1949.00 | 1850.00 | 1.0535 | 1.0966 |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 1806.00 | 1850.00 | 0.9762 | 0.9569 | |
| SK-BR-3 | 17-AAG | 3.1623 | uM | 7 | 1250.00 | 859.67 | 846.00 | 1850.00 | 0.4573 | -0.0144 |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 1619.00 | 1850.00 | 0.8751 | 0.7727 | |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 3.00 | 1850.00 | 0.0016 | -0.9940 | |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 5.00 | 1850.00 | 0.0027 | -0.9905 | |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 1816.00 | 1850.00 | 0.9816 | 0.9667 | |
| SK-BR-3 | 17-AAG | 10 | uM | 7 | 1250.00 | 859.67 | 885.00 | 1850.00 | 0.4784 | 0.0266 |
| SK-BR-3 | 17-AAG | 0.0016596 | uM | 7 | 1250.00 | 859.67 | 1760.00 | 1850.00 | 0.9514 | 0.9118 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 7 | 1250.00 | 859.67 | 1825.00 | 1850.00 | 0.9865 | 0.9755 |
| SK-BR-3 | Erlotinib | 0.01 | uM | 7 | 1250.00 | 859.67 | 1994.00 | 1850.00 | 1.0778 | 1.1403 |
| SK-BR-3 | 0 | uM | 7 | 1250.00 | 859.67 | 2093.00 | 1850.00 | 1.1314 | 1.2362 | |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 7 | 1250.00 | 859.67 | 1645.00 | 1850.00 | 0.8892 | 0.7985 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 7 | 1250.00 | 859.67 | 1951.00 | 1850.00 | 1.0546 | 1.0985 |